NYSE:BMY - Bristol-Myers Squibb Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$50.12 +0.52 (+1.05 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$50.12
Today's Range$48.94 - $50.33
52-Week Range$44.30 - $70.05
Volume20.41 million shs
Average Volume18.28 million shs
Market Capitalization$80.96 billion
P/E Ratio13.33
Dividend Yield3.31%
Beta0.98
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP11012210
Phone212-546-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.78 billion
Cash Flow$3.5546 per share
Book Value$7.24 per share

Profitability

Net Income$1.01 billion

Miscellaneous

Employees23,700
Outstanding Shares1,632,200,000
Market Cap$80.96 billion
OptionableOptionable

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 6th. Shareholders of record on Friday, January 4th will be given a dividend of $0.41 per share on Friday, February 1st. This represents a $1.64 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date of this dividend is Thursday, January 3rd. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.40. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) issued its quarterly earnings results on Thursday, October, 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.18. The biopharmaceutical company earned $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Bristol-Myers Squibb.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, January 24th at 10:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8004584121.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2019 earnings guidance on Thursday, January, 3rd. The company provided earnings per share guidance of $4.10-4.20 for the period.

What price target have analysts set for BMY?

20 brokers have issued 12-month target prices for Bristol-Myers Squibb's shares. Their forecasts range from $47.00 to $76.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $61.0894 in the next year. This suggests a possible upside of 21.9% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb.

What is the consensus analysts' recommendation for Bristol-Myers Squibb?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 12 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

News stories about BMY stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Bristol-Myers Squibb's key competitors?

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 58)
  • Mr. Joseph C. Caldarella, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 63)

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Retirement Systems of Alabama (0.09%), Douglas Lane & Associates LLC (0.08%), Hexavest Inc. (0.06%), RNC Capital Management LLC (0.05%), DNB Asset Management AS (0.04%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Gulf International Bank UK Ltd, Patten & Patten Inc. TN, RNC Capital Management LLC, Lodestar Investment Counsel LLC IL, Howard Capital Management, First American Trust FSB and 6 Meridian. View Insider Buying and Selling for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Atalanta Sosnoff Capital LLC, DNB Asset Management AS, Centre Asset Management LLC, Gradient Investments LLC, Stock Yards Bank & Trust Co., Town & Country Bank & Trust CO dba First Bankers Trust CO and Nachman Norwood & Parrott Inc. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $50.12.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $80.19 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is http://www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29th Street 14 Floor, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  881 (Vote Outperform)
Underperform Votes:  804 (Vote Underperform)
Total Votes:  1,685
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel